| アイテムタイプ |
default_学術雑誌論文 / Journal Article(1) |
| タイトル |
|
|
タイトル |
Promising probiotics for the treatment of nephrotoxicity induced during immune-checkpoint therapy against cancers |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
immune-related adverse events |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
immune checkpoint inhibitors |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
gut-kidney axis |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
gut-immune axis |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
short-chain fatty acids |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
D-amino acids |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
reactive oxygen species |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
metadata only access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_14cb |
| 著者 |
Yoshikawa Sayuri
Taniguchi Kurumi
Sawamura Haruka
Ikeda Yuka
Tsuji Ai
松田 覚
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
The immune-related adverse events resulting from the therapy of immune checkpoint inhibitors could cause kidney injury. Inflammatory reprogramming of regulatory T helper (Treg) cells or type 17 T helper (Th17) cells might be involved in the pathogenesis of nephropathy. Accumulating evidence confirms a connection between the diversity of gut microbiota and kidney diseases, suggesting that successful modification of gut microbiota could attenuate kidney injury. In other words, certain gut microbiota could contribute to the protection of kidneys via the gut-kidney axis. It has been shown that the dysbiosis of gut microbiota might affect the gut-kidney axis, leading to nephrotoxicity. On the contrary, altered levels of D-amino acids, ROS, and SCFAs through the adjustment of gut microbiota might be relevant to the reduction of nephrotoxicity. Here, we have discussed and suggested the beneficial roles of gut microbiota in the prevention of the kidney injury induced during immune-checkpoint therapy. |
|
言語 |
en |
| 書誌情報 |
en : AIMS Bioengineering
巻 9,
号 3,
p. 283-292,
発行日 2022
|
| 出版者 |
|
|
出版者 |
AIMS Press |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2375-1495 |
| DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.3934/bioeng.2022019 |
| 権利 |
|
|
権利情報 |
© the Author(s) |
|
言語 |
en |
https://doi.org/10.3934/bioeng.2022019
